Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Adrenocortical Carcinoma × cixutumumab × Clear all

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1 Adrenocortical Carcinoma 1 Adenocarcinoma of Lung 1

Interventions

Mitotane 2 pembrolizumab 1 cixutumumab 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Suramin 1 Nivolumab 1 Hydrocortisone 1 Dichlorodiphenyldichloroethane 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00778817 2014-04-29

IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated

20 enrolled 17 charts

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡